Search

Your search keyword '"Roquebert B"' showing total 9 results
Start Over Author "Roquebert B" Publication Year Range Last 3 years
9 results on '"Roquebert B"'

1. La vaginose bactérienne : importance d’un bon diagnostic

Author

D’humieres, C., primary, Ndeye-khady, K., additional, Goubard, A., additional, Hedbaut, E., additional, Guedon, D., additional, Pitois, G., additional, Nguyen huuy, H., additional, Stehle, M., additional, Roquebert, B., additional, and Haim-boukobza, S., additional

Published
2024
Full Text
View/download PDF

4. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

Author

Andrieu, A., Broustal, O., Chene, S., Chent, S., Fougère, E., Gbaguidi, G., Hamidouche, M., Lamy, A., Mano, Q., Mastrovito, B., Mercier, A., Modenesi, G., Picard, G., Prudhomme, J., Rapilly, F., Riondel, A., Rivière, M., Villegas Ramirez, B., Zhu-Soubise, A., Zurbaran, M., Amzert, A., Andreoletti, L., Bal, A., Beaurepere, R., Behillil, S., Belec, L., Bernard, C., Bocket, L., Bouri, L., Bourlet, T., Bressollette-Bodin, C., Brichler, S., Brugerolles, C., Cado, S., Calvez, V., Capron, N., Castelain, S., Castro-Alvarez, J., Chaix, M.-L., Charpentier, C., Che, D., Chillou, C., Colson, P., Coudene, P., Crinquette, A., De Rougemont, A., Delagrèverie, H., Delamare, C., Denecker-Berardino, T., Descamps, D., Desroches, M., Destras, G., Dos Santos, G., Ducancelle, A., Ducreux, S., Duret, T., Enouf, V., Fafi-Kremer, S., Felici, C., Fourati, S., Fournier, P.-E., Gaudy, C., Germain, H., Giordanengo, V., Gorge, O., Haim-Boukobza, S., Henquell, C., Holstein, A., Houhamdi, L., Izopet, J., Jacomo, V., Jacques, A., Jaffar-Bandjee, M.-C., Jimenez, M., Josset, L., Kemeny, S., Lafon, M.-E., Le Bars, A., Le Corguille, G., Lepiller, Q., Levasseur, A., Leveque, N., Lina, B., Madelaine, C., Malabat, C., Marque-Juillet, S., Martin-Dunavit, T., Mavingui, P., Merens, A., Messak, I., Morand-Joubert, L., Naudot, X., Neybecker, P., Pawlotsky, J.-M., Pilorge, L., Plantier, J.-C., Poggi, C., Pretet, M., Ragot, C., Raoul, H., Rogez, S., Roque-Afonso, A.-M., Roquebert, B., Rousset, D., Rozenberg, F., Sagot, C., Sahnoune, S., Salgado, D., Sand, O., Saudemont, C., Schvoerer, E., Simon-Loriere, E., Stephan, R., Sudour, J., Thibault, V., Tuaillon, E., Vabret, A., Vallee, E., Van Der Werf, S., Van Helden, J., Verdurme, L., Vignola, A., Wilkinson, D., Yazdanpanah, Y., Maisa, A., Spaccaferri, G., Fournier, L., Schaeffer, J., Deniau, J., Rolland, P., and Coignard, B.

Published
2022
Full Text
View/download PDF

5. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

Author

Maisa, A., primary, Spaccaferri, G., additional, Fournier, L., additional, Schaeffer, J., additional, Deniau, J., additional, Rolland, P., additional, Coignard, B., additional, Andrieu, A., additional, Broustal, O., additional, Chene, S., additional, Chent, S., additional, Fougère, E., additional, Gbaguidi, G., additional, Hamidouche, M., additional, Lamy, A., additional, Mano, Q., additional, Mastrovito, B., additional, Mercier, A., additional, Modenesi, G., additional, Picard, G., additional, Prudhomme, J., additional, Rapilly, F., additional, Riondel, A., additional, Rivière, M., additional, Villegas Ramirez, B., additional, Zhu-Soubise, A., additional, Zurbaran, M., additional, Amzert, A., additional, Andreoletti, L., additional, Bal, A., additional, Beaurepere, R., additional, Behillil, S., additional, Belec, L., additional, Bernard, C., additional, Bocket, L., additional, Bouri, L., additional, Bourlet, T., additional, Bressollette-Bodin, C., additional, Brichler, S., additional, Brugerolles, C., additional, Cado, S., additional, Calvez, V., additional, Capron, N., additional, Castelain, S., additional, Castro-Alvarez, J., additional, Chaix, M.-L., additional, Charpentier, C., additional, Che, D., additional, Chillou, C., additional, Colson, P., additional, Coudene, P., additional, Crinquette, A., additional, De Rougemont, A., additional, Delagrèverie, H., additional, Delamare, C., additional, Denecker-Berardino, T., additional, Descamps, D., additional, Desroches, M., additional, Destras, G., additional, Dos Santos, G., additional, Ducancelle, A., additional, Ducreux, S., additional, Duret, T., additional, Enouf, V., additional, Fafi-Kremer, S., additional, Felici, C., additional, Fourati, S., additional, Fournier, P.-E., additional, Gaudy, C., additional, Germain, H., additional, Giordanengo, V., additional, Gorge, O., additional, Haim-Boukobza, S., additional, Henquell, C., additional, Holstein, A., additional, Houhamdi, L., additional, Izopet, J., additional, Jacomo, V., additional, Jacques, A., additional, Jaffar-Bandjee, M.-C., additional, Jimenez, M., additional, Josset, L., additional, Kemeny, S., additional, Lafon, M.-E., additional, Le Bars, A., additional, Le Corguille, G., additional, Lepiller, Q., additional, Levasseur, A., additional, Leveque, N., additional, Lina, B., additional, Madelaine, C., additional, Malabat, C., additional, Marque-Juillet, S., additional, Martin-Dunavit, T., additional, Mavingui, P., additional, Merens, A., additional, Messak, I., additional, Morand-Joubert, L., additional, Naudot, X., additional, Neybecker, P., additional, Pawlotsky, J.-M., additional, Pilorge, L., additional, Plantier, J.-C., additional, Poggi, C., additional, Pretet, M., additional, Ragot, C., additional, Raoul, H., additional, Rogez, S., additional, Roque-Afonso, A.-M., additional, Roquebert, B., additional, Rousset, D., additional, Rozenberg, F., additional, Sagot, C., additional, Sahnoune, S., additional, Salgado, D., additional, Sand, O., additional, Saudemont, C., additional, Schvoerer, E., additional, Simon-Loriere, E., additional, Stephan, R., additional, Sudour, J., additional, Thibault, V., additional, Tuaillon, E., additional, Vabret, A., additional, Vallee, E., additional, Van Der Werf, S., additional, Van Helden, J., additional, Verdurme, L., additional, Vignola, A., additional, Wilkinson, D., additional, and Yazdanpanah, Y., additional

Published
2022
Full Text
View/download PDF

6. Variant-specific SARS-CoV-2 within-host kinetics.

Author

Elie B, Roquebert B, Sofonea MT, Trombert-Paolantoni S, Foulongne V, Guedj J, Haim-Boukobza S, and Alizon S

Subjects
Aged, Humans, Kinetics, Viral Load methods, COVID-19, SARS-CoV-2 genetics
Abstract

Since early 2021, SARS-CoV-2 variants of concern (VOCs) have been causing epidemic rebounds in many countries. Their properties are well characterized at the epidemiological level but the potential underlying within-host determinants remain poorly understood. We analyze a longitudinal cohort of 6944 individuals with 14 304 cycle threshold (Ct) values of reverse-transcription quantitative polymerase chain reaction (RT-qPCR) VOC screening tests performed in the general population and hospitals in France between February 6 and August 21, 2021. To convert Ct values into numbers of virus copies, we performed an additional analysis using droplet digital PCR (ddPCR). We find that the number of viral genome copies reaches a higher peak value and has a slower decay rate in infections caused by Alpha variant compared to that caused by historical lineages. Following the evidence that viral genome copies in upper respiratory tract swabs are informative on contagiousness, we show that the kinetics of the Alpha variant translate into significantly higher transmission potentials, especially in older populations. Finally, comparing infections caused by the Alpha and Delta variants, we find no significant difference in the peak viral copy number. These results highlight that some of the differences between variants may be detected in virus load variations., (© 2022 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

7. Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022.

Author

Sofonea MT, Roquebert B, Foulongne V, Morquin D, Verdurme L, Trombert-Paolantoni S, Roussel M, Bonetti JC, Zerah J, Haim-Boukobza S, and Alizon S

Subjects
France epidemiology, Humans, Virulence, COVID-19 epidemiology, SARS-CoV-2 genetics
Abstract

We analyzed 324,734 SARS-CoV-2 variant screening tests from France enriched with 16,973 whole-genome sequences sampled during September 1, 2021-February 28, 2022. Results showed the estimated growth advantage of the Omicron variant over the Delta variant to be 105% (95% CI 96%-114%) and that of the BA.2 lineage over the BA.1 lineage to be 49% (95% CI 44%-52%). Quantitative PCR cycle threshold values were consistent with an increased ability of Omicron to generate breakthrough infections. Epidemiologic modeling shows that, in spite of its decreased virulence, the Omicron variant can generate important critical COVID-19 activity in hospitals in France. The magnitude of the BA.2 wave in hospitals depends on the level of relaxing of control measures but remains lower than that of BA.1 in median scenarios.

Published
2022
Full Text
View/download PDF

9. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).

Author

Andries J, Viranaicken W, Cordonin C, Herrscher C, Planesse C, Roquebert B, Lagrange-Xelot M, El-Kalamouni C, Meilhac O, Mavingui P, Couret D, Gadea G, and Despres P

Subjects
Animals, BNT162 Vaccine, Humans, Liposomes, Mice, Nanoparticles, SARS-CoV-2 genetics, Antibodies, Viral immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, Epitopes, B-Lymphocyte, Spike Glycoprotein, Coronavirus immunology
Abstract

The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine COMIRNATY is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in COMIRNATY-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from COMIRNATY vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine COMIRNATY., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results